Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis by Ina Kramer et al.
MOLECULAR AND CELLULAR BIOLOGY, June 2010, p. 3071–3085 Vol. 30, No. 12
0270-7306/10/$12.00 doi:10.1128/MCB.01428-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Osteocyte Wnt/-Catenin Signaling Is Required for Normal
Bone Homeostasis
Ina Kramer,1 Christine Halleux,1 Hansjoerg Keller,1 Marco Pegurri,1 Jonathan H. Gooi,1
Patricia Brander Weber,2 Jian Q. Feng,3 Lynda F. Bonewald,4 and Michaela Kneissel1*
Musculoskeletal Disease Area1 and Pathology,2 Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel,
Switzerland; Department of Biomedical Sciences, Baylor College of Dentistry, Dallas, Texas3; and Department of Oral Biology,
University of Missouri at Kansas City, Kansas City, Missouri4
Received 30 October 2009/Returned for modification 17 December 2009/Accepted 5 April 2010
-Catenin-dependent canonical Wnt signaling plays an important role in bone metabolism by controlling
differentiation of bone-forming osteoblasts and bone-resorbing osteoclasts. To investigate its function in
osteocytes, the cell type constituting the majority of bone cells, we generated osteocyte-specific -catenin-
deficient mice (Ctnnb1loxP/loxP; Dmp1-Cre). Homozygous mutants were born at normal Mendelian frequency
with no obvious morphological abnormalities or detectable differences in size or body weight, but bone mass
accrual was strongly impaired due to early-onset, progressive bone loss in the appendicular and axial skeleton
with mild growth retardation and premature lethality. Cancellous bone mass was almost completely absent,
and cortical bone thickness was dramatically reduced. The low-bone-mass phenotype was associated with
increased osteoclast number and activity, whereas osteoblast function and osteocyte density were normal.
Cortical bone Wnt/-catenin target gene expression was reduced, and of the known regulators of osteoclast
differentiation, osteoprotegerin (OPG) expression was significantly downregulated in osteocyte bone fractions of
mutant mice. Moreover, the OPG levels expressed by osteocytes were higher than or comparable to the levels
expressed by osteoblasts during skeletal growth and at maturity, suggesting that the reduction in osteocytic
OPG and the concomitant increase in osteocytic RANKL/OPG ratio contribute to the increased number of
osteoclasts and resorption in osteocyte-specific -cateninmutants. Together, these results reveal a crucial novel
function for osteocyte -catenin signaling in controlling bone homeostasis.
The adult skeleton is continuously remodeled in a tightly
regulated manner by the coupled activity of bone-resorbing
osteoclasts and bone-forming osteoblasts to maintain skeletal
integrity and bone homeostasis (24, 46). A similar complex
regulatory network of defined, but not necessarily coupled,
osteoblast and osteoclast action is required during develop-
ment and growth, when bone modeling ensures functional
bone morphology and bone mass accrual, which in mice occurs
throughout the first 3 to 4 months of life until peak bone mass
is reached.
Osteoblasts differentiate from mesenchymal bone marrow
progenitor cells into bone-forming osteoblasts that reside on
the bone surface and deposit new bone matrix. In contrast,
osteoclasts are derived from hematopoietic bone marrow pre-
cursor cells that belong to the myeloid monocyte/macrophage
lineage (63). However, the majority, i.e., more than 90 to 95%
of all bone cells in the adult skeleton, are osteocytes (10),
terminally differentiated cells of the mesenchymal osteoblast
lineage residing in small lacunae found at regular intervals
within the mineralized bone matrix. They extend long thin
cellular protrusions or dendrites, which travel through small
channels (canaliculi) inside the compact bone, but also reach
the bone surface and bone marrow compartment (8, 30). By
forming gap junctions to neighboring cells, osteocytes are con-
nected not only to each other but also to cells on the bone
surface, including osteoblasts, bone lining cells, and possibly
osteoclasts. They thus form a complex cellular network that
seems ideally suited for mechanosensation and integration of
local and systemic signals to ensure skeletal integrity and bone
homeostasis (9, 10). Moreover, it was recently demonstrated
that bone homeostasis and adaptation to regular or diminished
skeletal loading are strongly disturbed in mice selectively de-
pleted of osteocytes (61). Therefore, while osteocytes are cel-
lular descendants of former bone matrix-producing osteo-
blasts, osteocytes have a unique cellular identity that is
reflected by their specific location inside the bone matrix, their
specialized cellular morphology adapted to being trapped in
the mineralized bone compartment, and finally a specific mo-
lecular signature that clearly distinguishes osteoblasts and os-
teocytes from each other (52).
Wnt/-catenin signaling, which is also known as canonical
Wnt signaling, is a key signaling pathway required for normal
bone and cartilage formation and for bone homeostasis (40,
55). Canonical Wnt signaling is initiated by secreted Wnt li-
gands binding to a dual-receptor complex formed by low-den-
sity lipoprotein receptor-related protein 5 or 6 (Lrp5/6) and
the seven-transmembrane domain receptor frizzled. This trig-
gers a downstream signaling cascade leading to inhibition of
cytoplasmic glycogen synthase kinase 3 (GSK3), which in
turn relieves -catenin, the central mediator of canonical Wnt
signaling, from its constitutive proteosomal degradation.
-Catenin then accumulates in the cytoplasm and translocates
into the nucleus where it associates with members of the T-
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cell-specific transcription factor (TCF)/lymphoid enhancer
binding factor (Lef) family to control Wnt/-catenin target
gene transcription. In contrast to canonical Wnt signaling, non-
canonical Wnt signaling is -catenin independent and can ac-
tivate several downstream pathways, including the Wnt/planar
cell polarity and the Wnt-cGMP/Ca2 pathway (17, 55).
In bone, both canonical Wnt signaling and noncanonical
Wnt signaling are involved in the control of osteoblastogenesis,
although the role of noncanonical Wnt signaling is still less
understood (17, 55). Canonical Wnt/-catenin signaling is re-
quired for commitment of mesenchymal stem cells to the os-
teoblast lineage and for osteoblastic precursor proliferation
and differentiation (18, 19, 25–27). Conditional deletion of the
-catenin gene in osteoblasts in vivo using alpha 1 type I colla-
gen Cre (Col11-Cre) (19) or osteocalcin-Cre (OC-Cre) (26)
revealed an essential function for -catenin-dependent Wnt
signaling in controlling osteoclast differentiation and bone ho-
meostasis, respectively. Osteoblast-specific -catenin-deficient
mice develop a low-bone-mass phenotype due to increased
osteoclastic bone resorption as a result of decreased expression
of the osteoclast differentiation inhibitor osteoprotegerin
(OPG). Since in these mouse models, -catenin function was
deleted not only in osteoblasts but also in the cellular progeny
of the mesenchymal osteoblast lineage, including osteocytes
and bone lining cells, the relative contributions of these cell
types to the observed bone resorption phenotype and the spe-
cific role of Wnt/-catenin signaling in osteoblasts versus their
descendants remain to be addressed in detail. Previous studies
have implicated Wnt/-catenin signaling in osteocyte mech-
anosensation, as Wnt/-catenin signaling is activated upon me-
chanical loading in osteocytes and is generally assumed to be a
major signaling pathway required for mechanotransduction in
bone in vivo (9, 11, 39, 56–58).
To determine the in vivo function of -catenin in osteocytes,
we generated osteocyte-specific -catenin loss-of-function mice
by crossing mice with a floxed -catenin gene (13) with Dmp1-
Cre transgenic mice expressing Cre recombinase selectively in
osteocytes (42). Here, we report that mice in which -catenin
has been conditionally knocked out in osteocytes (-catenin
cKO mice) develop an early-onset, severe low-bone-mass phe-
notype that is caused by elevated osteoclastic bone resorption
mimicking the previously reported osteoblast-specific -cate-
nin loss-of-function phenotype (19, 26). Therefore, selective
deletion of the -catenin gene in the late-stage mesenchymal
osteoblast lineage, i.e., in terminally differentiated osteocytes,
is as detrimental to the skeleton as its earlier loss in the lin-
eage, i.e., in osteoblasts, revealing an essential novel function
for -catenin signaling specifically in osteocytes that is required
for normal bone homeostasis in vivo.
MATERIALS AND METHODS
Mice. Mice with the targeted -catenin gene, in which exons two to six of the
-catenin gene are located within loxP sites (Ctnnb1loxP/loxP), were obtained from
the Jackson Laboratory (13). Dmp1-Cre transgenic mice expressing Cre under
the control of a 14-kb regulatory fragment of the osteocyte marker gene
Dmp1 have been previously described (42) and were maintained on a mixed
CD1-C57BL/6 background. Heterozygous osteocyte-specific -catenin cKO
mice (Ctnnb1/loxP; Dmp1-Cre) generated from crosses of both mouse lines were
backcrossed with Ctnnb1loxP/loxP mice, and the progeny were analyzed. Data
obtained from heterozygous and homozygous floxed -catenin littermates lacking
Dmp1-Cre were pooled and used as controls. In addition, 4-month-old C57BL/
6JOlaHsd female mice from Charles River Laboratories, Germany, were ob-
tained for isolation of adult femoral osteoblast- and osteocyte-enriched cell
fractions. All mice were kept in cages under standard laboratory conditions with
a constant temperature of 22°C and a cycle of 12 h of light and 12 h of dark. The
mice were fed a standard rodent diet (catalog no. 3302; Provimi Kliba SA,
Switzerland) with water ad libitum. Protocols, handling, and care of the mice
conformed to the institutional policies and the Swiss federal law for animal
protection under the control of the Basel-Stadt Cantonal Veterinary Office,
Switzerland.
Radiography and microcomputed tomography (CT) analyses. Whole-body
radiographs were taken after sacrifice of the animals in lateral and frontal
positions (high-resolution MX-20 specimen radiography system; Faxitron, Buf-
falo Grove, IL). Generation of three-dimensional (3D) bone reconstruction
images and evaluation of bone structure were accomplished by ex vivo measure-
ments using a Scanco vivaCT40 (voxel size, 10.5 m; high resolution; Scanco
Medical). For cancellous and cortical bone analyses, fixed thresholds of 225 and
300, respectively, were used to determine the mineralized bone fraction. A
Gaussian filter was applied (  0.7; support  1) to remove noise, and 30 slices
were evaluated.
Peripheral quantitative computed tomography (pQCT) analyses. Cross-sec-
tional total bone mineral density (BMD), bone mineral content (BMC), and
cortical thickness were evaluated in five consecutive slices spaced 1.8 to 2 mm
apart along the long bone axis of the left femur using an adapted Stratec-Norland
XCT-2000 fitted with an Oxford (Oxford, United Kingdom) 50-m X-ray tube
(GTA6505M/LA) and a collimator with a 0.5-mm diameter. The following setup
was chosen for the measurements: voxel size, 0.07 mm by 0.07 mm by 0.4 mm;
scan speed scout view, 10 mm/s; final scan, 5 mm/s, 1 block, contour mode 1, peel
mode 2; and cortical and inner threshold, 350 mg/cm3.
Bone histomorphometry. All mice received fluorochrome markers by subcu-
taneous injection 10 days (alizarin complexone [Merck]; 20 mg/kg of body
weight) and 3 days prior to necropsy (calcein [Fluka]; 30 mg/kg) to evaluate bone
formation dynamics. The left femur was fixed for 24 h in 4% phosphate-buffered
paraformaldehyde, dehydrated, defattened at 4°C, and embedded in methyl-
methacrylate resin. For each animal, a set of 5-m nonconsecutive longitudinal
sections was cut in the frontal midbody plane (Leica RM2155 microtome; Leica
Microsystems). Fluorochrome marker-based dynamic bone parameters were de-
termined using a Leica DM microscope fitted with a Sony DXC-950P camera
and adapted Quantimet 600 software (Leica). Microscopic images of the speci-
men were digitized and evaluated semiautomatically (200 magnification) as
previously described (33). The bone surface, single- and double-labeled bone
surface, and interlabel width were measured in the cancellous bone compartment
and at the endocortex of the distal femur metaphysis. Mineralizing surface was
calculated as follows: MS/BS  [(dLS  sLS/2)/BS]  100, where MS is the
mineralizing surface, BS is the bone surface, and dLS and sLS are the double-
labeled and single-labeled bone surface, respectively. The mineral apposition
rate (MAR) (m/day) in the cancellous bone compartment corrected for section
obliquity was calculated, and the daily bone formation rate (BFR/BS, where BFR
is the bone formation rate) (m/day) was derived. Osteoblast and osteoid surface
per bone surface and the number of osteocytes per cortical bone area were
determined on Goldner-stained sections. Osteoclast number was determined on
5-m femoral microtome sections stained for tartrate-resistant acid phosphatase
(TRAP) activity. Bone histomorphometric nomenclature was applied as recom-
mended by Parfitt et al. (53).
General histopathology and whole-mount skeletal staining. Tissue and organ
samples (lungs, heart, liver, gallbladder, kidneys, urinary bladder, ovaries, uterus,
vagina, brain, thymus, spleen, pancreas, tongue, stomach, small and large intes-
tine, mesenteric and mandibular lymph nodes, trachea, esophagus, aorta, skin,
mammary gland area, skeletal muscle, peripheral nerve, adrenal glands, pituitary
gland, thyroid with parathyroid glands, eyes, Harderian glands, lacrimal glands,
sternum, and humerus with elbow joint) from homozygous and heterozygous
mutant and control mice were fixed in neutral phosphate-buffered formalin, and
the bones were demineralized with formic acid. All fixed organs/tissues were
trimmed, embedded in paraffin wax, sectioned, and stained with hematoxylin and
eosin (H&E) to determine histopathological phenotypic abnormalities. Whole-
body skeletal staining of cartilage and bone with alcian blue and alizarin red S
was performed as previously described (28).
TUNEL and immunofluorescence staining. The femora of mutant and control
pups (three per group) were dissected, fixed in 4% paraformaldehyde in 0.1 M
phosphate buffer, decalcified for 3 days (15% EDTA–0.5% paraformaldehyde),
cryoprotected, and embedded in Tissue-Tek optimum-cutting-temperature
(O.C.T.) compound (Sakura Finetek). Five-micrometer cryostat sections ob-
tained with the CryoJane tape-transfer system (Instrumedics) were processed for
detection of apoptotic osteocytes based on terminal deoxynucleotidyltransferase-
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mediated dUTP-biotin nick end labeling (TUNEL) technology using the in situ
cell death detection kit with fluorescein (Roche Applied Science), followed by
overnight incubation at 4°C with goat anti-sclerostin (R&D Systems) primary
antibody in 10% normal donkey serum in phosphate-buffered saline (PBS) con-
taining 0.1% Triton X-100 and fluorophore-conjugated secondary antibodies
according to standard procedures. Images were collected on a Leica TCS SP2
confocal microscope.
Clinical blood biochemistry, serum bone biomarkers, and RANKL determi-
nation. Blood samples for clinical biochemistry, alkaline phosphatase (ALP),
osteocalcin, and receptor activator of NF-B ligand (RANKL) assessment and
for determination of C-telopeptide fragments of collagen type I (CTX-I) and
TRAP activity were collected under CO2 narcosis by heart puncture. Clinical
biochemistry parameters, including serum ALP levels, were determined with a
Synchron CX5 analyzer or a COBAS MIRA S system using standard test kits
(Roche Diagnostics; Axon Lab). Serum osteocalcin concentration was quantified
using an immunoradiometric assay (IRMA) kit (Immutopics). Free RANKL
levels, i.e., the levels of RANKL not bound to osteoprotegerin (OPG), were
measured by enzyme-linked immunosorbent assay (ELISA) (R&D Systems)
according to the manufacturer’s instructions with the detection minimum being
below 5 pg/ml. Serum CTX-I concentration and TRAP activity were determined
by ELISA (Immunodiagnostic Systems).
RNA extraction and quantitative real-time PCR (qPCR) expression analyses.
Total RNA from mutant and control mice was isolated from cortical bone of
femoral diaphyses as previously described (32). Osteoblast and osteocyte selec-
tive total RNA was isolated by sequential enzymatic digestion of adult wild-type
femora using a modified version of the protocol of Gu et al. (21). Briefly, the soft
tissue and periosteum were removed, epiphyses were cut off, and bone marrow
was flushed with PBS. The diaphyses were incubated at 37°C for 20 min with
shaking in 0.2% collagenase type IV (Sigma) in isolation buffer containing 25
mM HEPES (pH 7.4), 70 mM NaCl, 10 mM NaHCO3, 60 mM sorbitol, 30 mM
KCl, 3 mM K2HPO4, 1 mM CaCl2, 0.1% bovine serum albumin (BSA), and 0.5%
glucose followed by rinsing with PBS. Supernatants were collected and centri-
fuged at 800  g for 8 min, and cell pellets were resuspended in TRIzol
(Invitrogen) and frozen at 	80°C (fraction 1). The remaining diaphyses were
digested in PBS containing 5 mM EDTA and 0.1% BSA at 37°C for 20 min and
rinsed once with PBS, and supernatants were collected and stored as described
above (fraction 2). The diaphyses were then incubated twice in 0.2% collagenase
solution at 37°C for 30 min for femora from 6-week-old mice or for 60 min for
femora from 4-month-old mice and rinsed with PBS, and the supernatants were
collected and stored as before to yield fractions 3 and 4. Fraction 5 was obtained
following digestion of the diaphyses in PBS containing 5 mM EDTA and 0.1%
BSA at 37°C for another 30 min for femora from 6-week-old or for 45 min for
femora from 4-month-old mice. The cells were collected as described above. The
remaining femoral diaphyses were transferred into TRIzol together with 5-mm
stainless steel beads (Qiagen), homogenized using a FastPrep FP120 homoge-
nizer (Thermo Scientific) at speed 5 for 30 s, and stored at 	80°C (fraction 6).
Total RNA was extracted from cell fractions 1 to 6 according to the manufac-
turer’s recommendations followed by DNase I treatment and RNA cleanup using
the RNase-free DNase set and RNeasy MinElute cleanup kits (Qiagen), respec-
tively. Total RNA was reverse transcribed with the high-capacity cDNA re-
verse transcription kit (Applied Biosystems) according to the manufacturer’s
protocol. Gene expression analyses were performed with an ABI Prism 7900HT
sequence detection system (Applied Biosystems) using TaqMan universal PCR
master mix and mouse TaqMan probes according to the manufacturer’s instruc-
tions (Applied Biosystems).
Statistical analyses. All data shown represent means plus standard errors of
the means (SEMs). Statistical analyses were performed using Student’s t tests
(two-tailed) or one-way analysis of variance (ANOVA).
RESULTS
Generation of osteocyte-specific -catenin loss-of-function
mice. To investigate the role of -catenin in osteocytes in vivo,
we generated osteocyte-specific -catenin loss-of-function mice
by crossing conditional -catenin mutant mice (13) with Dmp1-
Cre mice expressing Cre recombinase selectively in osteocytes
under the control of a 9.6-kb promoter fragment of the
dentin matrix protein 1 (Dmp1) osteocytic marker gene (42,
62). Homozygous osteocyte-specific -catenin mutant mice
(Ctnnb1loxP/loxP; Dmp1-Cre) were born at normal Mendelian
frequency (data not shown) with no obvious morphological
abnormalities or detectable differences in size or body weight
relative to control littermates (Fig. 1A and D). Perinatal skel-
etal examination by whole-body skeletal radiography and skel-
etal staining did not reveal any distinct phenotypic differences
in bone density or overall distribution of cartilaginous and
bony tissue in mutant versus control pups (Fig. 1B and C).
Similarly, femoral length and width were comparable between
osteocyte-specific -catenin conditional knockout (cKO) and
control littermate mice (Fig. 1E), consistent with little to no
Dmp1-Cre activity in osteocytes during embryonic develop-
ment (42).
Osteocyte-specific deletion of Wnt/-catenin signaling
induces progressive bone loss and premature lethality. We
monitored the overall bone phenotype of homozygous osteo-
cyte-specific -catenin-deficient mice compared to control lit-
termates during skeletal growth by whole-body skeletal radi-
ography and microcomputed tomography (CT) imaging of
the tibia. A progressive loss of bone density was detected
throughout the skeleton in mice lacking -catenin in osteocytes
(Fig. 2 and Fig. 3A and B). Three-dimensional CT recon-
struction images of the proximal tibia half revealed that bone
loss occurred throughout the tibia ranging from the midshaft to
the proximal metaphysis, including the epiphysis (Fig. 3A and
B). In growing female mice, the loss of bone mass appeared to
be even more severe than in male mice. In addition, homozy-
gous mutant female mice were slightly smaller in overall body
FIG. 1. Analysis of newborn osteocyte-specific -catenin gene cKO
mice. (A and B) Representative photographic images (A) and whole-
body skeletal radiographies (B) of postnatal day 1 (P1) homozygous
osteocyte-specific -catenin-deficient (cKO) and control mice.
(C) Whole-mount skeleton staining of P2 homozygous (cKO) and
heterozygous (HET) osteocyte-specific -catenin cKO and control
mice. (D and E) Quantification of body weight (D) and femoral length
and width (E) of P1 cKO and control littermates. The values are means
plus standard errors of the means (error bars). There were six mice in
each group.
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size than control littermate females. While the femoral bone
length was normal at birth, it decreased significantly by about
11% in male mice and 15% in female mice in 2-month-old
osteocyte-specific -catenin-deficient mice relative to heterozy-
gous mutant or control littermate mice (Fig. 3C). The cross-
sectional total bone mineral content (BMC) in the distal femur
metaphysis was significantly reduced by about 40% in homozy-
gous mutants of either sex compared to control mice (Fig. 3D).
Moreover, in both sexes, body weight decreased by about 35%
in homozygous, but not in heterozygous, mutant mice relative
to controls (Fig. 3E). Correspondingly, homozygous osteocyte-
specific loss of -catenin resulted in premature lethality at
about 3 months of age with only a few individual animals,
mostly male mice, surviving up to 5 months of age (Fig. 2 and
data not shown).
Since high Dmp1-targeted Cre expression has been reported
in odontoblasts (42), we next characterized jaw and tooth
structures of 2-month-old -catenin mutant and control mice.
Surprisingly, and in contrast to the distinct phenotypic abnor-
malities in the appendicular and axial skeleton, the incisors
appeared normal in -catenin-deficient mice (Fig. 2 and data
not shown). Therefore, feeding the mice a hard or soft diet had
no effect on their skeletal phenotype.
To further investigate the underlying basis of the observed
premature lethality and to exclude any extraskeletal pheno-
typic abnormalities possibly induced by Dmp1-Cre-mediated
deletion of -catenin, we subjected 2- and 3-month-old mutant
and control littermates to a full histopathological analysis.
Consistent with osteocyte-specific deletion of -catenin, geno-
type-related histopathological findings were present only in
skeletal tissue of homozygous -catenin-deficient mice. No ab-
normal findings were present in the other tissues and organs
investigated, including the heart and vasculature (data not
shown). Thus, extraskeletal defects do not appear to underlie
the premature lethality observed in homozygous -catenin mu-
tants. Skeletal defects were manifold with moderate to marked
bone thinning and accompanying skeletal deformation and
fractures in the appendicular and axial skeleton. Consistent
with frequent skeletal fractures and associated muscle injury,
serum creatine kinase levels were increased by about 175% in
2-month-old -catenin-deficient female mice (1.8 microkatals
[Kat]/liter for control females and 4.9 Kat/liter for cKO
females; P 
 0.01) and increased but not significantly by about
40% in mutant male mice (1.7 Kat/liter for control males and
2.4 Kat/liter for cKO males), respectively. In contrast, no
significant differences in the calcium and phosphorus concen-
trations were observed (data not shown).
We next analyzed canonical Wnt signaling target gene ex-
pression in cortical bone of femoral diaphyses. As expected,
-catenin expression was significantly decreased in homozy-
gous osteocyte-specific -catenin cKO female mice relative to
control mice (Fig. 4A). Consistent with the loss of -catenin
FIG. 2. Time course of the skeletal phenotype of osteocyte-specific -catenin cKO mice. Representative whole-body skeletal radiographies of
5-week-old (A to D), 8-week-old (E and F), 12-week-old (G to J), and 15-week-old (K and L) homozygous osteocyte-specific -catenin-deficient
(cKO) and control littermate female (A, B, G, and H) and male (C to F and I to L) mice.
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FIG. 3. Analysis of juvenile osteocyte-specific -catenin cKO mice. (A and B) Representative whole-body skeletal radiographies (left two
columns) and CT images of the proximal tibia to the midshaft level (right two columns) of 1-month-old (top row) and 2-month-old (bottom row)
homozygous osteocyte-specific -catenin-deficient (cKO) and control littermate male mice (A) and female mice (B). (C to E) Quantification of
femoral length (C), cross-sectional total BMC in the distal femur metaphysis (D), and body weight (E) of 2-month-old homozygous (cKO) and
heterozygous (HET) osteocyte-specific -catenin-deficient and control littermates. There were 3 to 11 mice in a group. Values for the mutant that
were significantly different from the value for control littermate mice of the same gender using unpaired Student’s t tests are shown as follows: *,
P 
 0.05; **, P 
 0.01.
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function, known target genes of Wnt/-catenin signaling, such
as Axin2 (29, 36, 43) and Smad6 (70), were also significantly
downregulated by about 30 to 60%, respectively, in homozy-
gous mutants relative to control mice (Fig. 4B and C). In
accordance with the mostly normal bone phenotype, neither
-catenin expression nor Axin2 or Smad6 expression was sig-
nificantly downregulated in heterozygous osteocyte-specific
-catenin-deficient mice compared to controls.
Osteocyte-specific deletion of -catenin causes cortical and
cancellous bone loss in the appendicular and axial skeleton.
We further characterized the low-bone-mass phenotype in
2-month-old osteocyte-specific -catenin-deficient mice by per-
forming ex vivo multiple-slice peripheral quantitative com-
puted tomography (pQCT) and high-resolution CT analyses
of the appendicular and axial skeleton. In homozygous -cate-
nin mutant mice, femoral cross-sectional total bone mineral
density (BMD) was significantly reduced by about 35 to 45% in
males (data not shown) and 40 to 55% in females (Fig. 4D),
depending on the respective femoral position analyzed. Het-
erozygous loss of osteocyte -catenin function did not signifi-
cantly alter BMD compared to control littermates of either sex
(Fig. 4D and data not shown). Similarly, cortical thickness as
assessed by high-resolution CT was reduced by about 20% in
the distal femur metaphysis and by about 35% in the distal
diaphysis of homozygous mutant female mice relative to con-
trol animals (Fig. 4E). Moreover, in the distal femur meta-
physis, the relative cortical bone volume was significantly
smaller by about 12%. Metaphyseal cortical bone density was
significantly reduced by about 13% compared to control mice,
and diaphyseal cortical bone density was mildly yet significantly
reduced by about 6% (data not shown). Reduction in cortical
bone density was related to cortical porosity in the cKO ani-
mals, while bone material density was unaltered (data not
shown). Consequently, as observed in the tibia (Fig. 3A and B),
3D reconstruction of the entire femur by CT imaging re-
vealed focal cortical thinning in homozygous osteocyte-specific
-catenin cKO mice of either sex to the extent that at certain
sites cortical bone was completely absent, resulting in distinct
perforations of the cortical shell being most severe in the
metaphyseal regions (Fig. 4F and data not shown). Moreover,
a dramatic lack of nearly all cancellous bone structures (tra-
beculae) was detected in homozygous osteocyte-specific
-catenin mutants of either sex (Fig. 4F and G). While the
number of trabeculae decreased by over 95%, trabecular thick-
ness and material BMD of the few remaining trabeculae were
not significantly altered in homozygous osteocyte-specific
-catenin-deficient mice compared to control mice (Table 1).
Interestingly, relative cancellous bone volume decreased by
about 10% in heterozygous male mice and almost 25% in
heterozygous female mice relative to control littermates (Fig.
4G), demonstrating slightly enhanced sensitivity to -catenin
gene dosage reduction in female mice compared to male mice.
Vertebral cancellous bone volume was almost completely ab-
sent in homozygous osteocyte-specific -catenin cKO mice rel-
ative to control mice of either sex (Fig. 4H and I). Conse-
quently, vertebral fractures and fibrotic scar tissue formation
were frequently observed, while the overall bone marrow com-
position was normal in homozygous -catenin mutants (Fig. 4H
and data not shown). Osteocyte-specific heterozygosity of
-catenin function caused a significant reduction of about 20%
in lumbar vertebra L3 cancellous bone volume in both sexes
(Fig. 4I).
Osteocyte-specific deletion of -catenin causes increased
osteoclastic bone resorption. To determine whether bone loss
induced by osteocyte-specific -catenin deficiency was due to
enhanced bone resorption, altered bone formation, or a com-
bination of the two, we next performed static and dynamic
bone histomorphometry on the distal femur metaphyses of
2-month-old mice. At the endocortex, the number of oste-
oclasts as determined by quantification of TRAP-positive cells
strongly increased by over four- to fivefold in homozygous
-catenin mutant mice of either sex (Fig. 5A and B). The
relative osteoclast surface was similarly increased by five- to
sevenfold in homozygous -catenin mutant male and female
mice compared to control animals (Table 2). Consequently,
the relative eroded bone surface as a measure of osteoclastic
bone resorption was elevated by about 8-fold in homozygous
mutant male and over 35-fold in mutant female mice, while
double-labeled bone surface and mineralizing surface reflect-
ing sites of active bone mineralization significantly decreased
by about 35% and 27% in mutant male mice and almost 55%
and 45% in homozygous -catenin-deficient female mice rela-
tive to controls (Table 2). These results are however likely
impacted by the extreme nature of bone resorption, which even
in the short 1-week interval between the application of the two
fluorochrome labels probably led to removal of part of the
bone containing fluorochrome markers.
We then determined the number of osteoclasts in the can-
cellous bone compartment. In homozygous mutant female
mice, essentially the entire cancellous bone was lost, and
growth plates were either missing or severely damaged, in line
with the mild growth retardation observed in homozygous mu-
tant animals (Fig. 3B and C, Fig. 4F and G, and data not
shown). We therefore limited our histomorphometric evalua-
tion of the cancellous bone compartment to male mice in
which the overall bone phenotype although similar was slightly
less severe. On the very few remaining trabeculae, the number
of osteoclasts increased by about 10% but not statistically sig-
nificant (Fig. 5C and D). Osteoclast morphology was compa-
rable between genotypes in both bone compartments (Fig. 5B
and D and data not shown). Double-labeled surface and min-
eralizing trabecular bone surface were mildly decreased by
about 10% (not statistically significant) in homozygous cKO
relative to control males (Table 1). Moreover, osteoblast
and osteoid surface, the latter representing newly deposited
unmineralized collagenous extracellular matrix, were ele-
vated by about 85% in the cancellous bone compartment
and by about 20% (not statistically significant) at the en-
docortex in mutant males compared to control littermates
(Tables 1 and 2). Likewise, osteoblastic mineral apposition
rate was increased by about 30 to 45% in both bone com-
partments (Tables 1 and 2), and bone formation rates were
comparable between osteocyte-specific -catenin mutant
and control littermate males (Fig. 5E and F), indicating
normal to slightly elevated osteoblast number and activity.
In female mice, relative osteoblast and osteoid surfaces were
not significantly different at the endocortex of homozygous
mutant compared to control mice (Table 2). Similar to male
mice, osteoblastic mineral apposition rate reflecting osteoblast
performance was significantly increased by about 40% at the
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FIG. 4. Characterization of femoral and vertebral bone of osteocyte-specific -catenin cKO mice. (A to C) Relative expression normalized to
18S for -catenin (A) and downstream Wnt/-catenin target genes Axin2 (B) and Smad6 (C) in cortical femoral bone from 2-month-old female
mice. (D and E) Femoral cross-sectional total BMD (D) and cortical thickness (E) of 2-month-old homozygous (cKO) and heterozygous (HET)
-catenin-deficient and control littermate female mice as evaluated by ex vivo pQCT analyses (D) of five consecutive slices S1 to S5 spaced equally
along the femoral axis from the distal metaphysis (S1) to the proximal end of the diaphysis (S5) or by ex vivo CT analyses (E) in the distal
metaphysis and diaphysis. (F) Representative CT images of the femur from 2-month-old homozygous -catenin-deficient (cKO) and control
littermate female mice. (G and I) Quantification of relative cancellous bone volume in the distal femur metaphysis with representative 3D-
reconstructed CT images from male mice (G) and lumbar vertebra L3 (I) of 2-month-old homozygous (cKO) and heterozygous (HET)
-catenin-deficient and control littermates. (H) Representative H&E stained images of thoracic vertebrae from 3-month-old homozygous cKO and
control female mice depicting a vertebral fracture (arrowhead) and extensive scar tissue formation (arrow). The boxes outlined by a broken line
in the top row are shown at higher magnification in the bottom row. There were 3 to 11 mice in each group. Values for the mutant that were
significantly different from the value for control littermate mice using unpaired Student’s t tests are shown as follows: *, P 
 0.05; **, P 
 0.01.
Bars, 1 mm (F, top row), 0.5 mm (F, bottom row), 0.5 mm (G), 0.25 mm (H, magnified view).
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endocortex of homozygous mutant female mice compared to
control mice (Table 2). However, since the relative mineraliz-
ing surface was decreased (Table 2), probably as a result of the
vast increase in bone resorption, the overall bone formation
rate was not significantly different in homozygous cKO female
mice compared to control mice (Fig. 5E).
Finally, to further assess osteoclast and osteoblast function
in osteocyte-specific -catenin loss-of-function mice, we mea-
sured serum bone biomarkers. Serum tartrate-resistant acid
phosphatase (TRAP) activity was increased by about 25% (not
significantly statistically) in 2-month-old homozygous osteocyte
-catenin-deficient male mice (3.4 U/liter in control males and
4.2 U/liter in cKO males) and by about 55% in cKO female
mice (1.7 U/liter in control females and 2.7 U/liter in cKO
females). Similarly, the concentration of C-telopeptide frag-
ments of collagen type I (CTX-I) was elevated by about 55%
(not significantly statistically) in 2.5-month-old mutant male
mice (75.6 ng/ml in control males and 116.6 ng/ml in cKO
males) and by about 35% in 2-month-old mutant female mice
(53.7 ng/ml in control females and 73.0 ng/ml) in cKO females.
Serum osteocalcin levels as a biomarker for active osteoblastic
bone formation were comparable in hetero- and homozygous
osteocyte-specific -catenin mutant mice (Fig. 5G). Serum al-
kaline phosphatase (ALP) activity was not significantly differ-
ent in mutant male mice but was mildly increased by about
15% in homozygous osteocyte-specific -catenin mutant fe-
male mice (Fig. 5H), consistent with overall normal to slightly
elevated osteoblast activity.
Osteocyte density is normal in osteocyte-specific -catenin
loss-of-function mice. Osteocyte apoptosis has been shown to
result in increased osteoclast recruitment and bone resorption
(1, 16, 20, 22, 34, 49, 61). We therefore determined the levels
of expression of the apoptosis facilitators Bcl2-like 11/Bim and
BCL2-associated X protein (Bax) (38, 65) in femoral diaphyses
of 2-month-old mutant and control female mice. Neither Bcl2-
like 11/Bim nor Bax expression were significantly altered in
osteocyte-specific -catenin mutant mice relative to control
mice (Fig. 6A and B). We next quantified cortical osteocyte
density in femoral cortical bone from 2-month-old hetero- and
homozygous osteocyte-specific -catenin-deficient and control
mice (Fig. 6C). Cortical osteocyte density was normal irrespec-
tive of osteocyte -catenin gene dosage. Moreover, osteocyte
apoptosis was low, and no major differences were detected in
-catenin mutant femora compared to controls (Fig. 6D), as
assessed in 2-week-old mice by TUNEL staining combined
with immunofluorescence detection of the osteocyte marker
sclerostin (64, 68). Similarly, we did not find any evidence for
increased presence of empty osteocyte lacunae in 2-month-old
homozygous -catenin cKO mice relative to control mice (data
not shown). Thus, osteocyte-specific loss of -catenin gene
function does not appear to result in significantly elevated
apoptotic or necrotic osteocyte death.
Osteocyte-specific deletion of Wnt/-catenin signaling
causes decreased OPG expression. Osteoclast differentiation
from osteoclast progenitors is controlled by the action of two
major cytokines, macrophage colony-stimulating factor (M-
CSF) and receptor activator of NF-B ligand (RANKL) (63),
both of which are expressed by cells of the osteoblast lineage
and stromal cells. Moreover, osteoblasts also secrete osteopro-
tegerin (OPG), a soluble RANKL decoy receptor that antag-
onizes the proosteoclastogenic activity of RANKL by prevent-
ing it from binding to its cognate RANK receptor present on
osteoclasts and their precursor cells (12). Thus, the relative
RANKL/OPG ratio determines bone mass and strength, and
high OPG levels are protective against excessive osteoclastic
bone resorption. Therefore, we next characterized the relative
levels of expression of M-CSF, RANKL, and OPG in cortical
bone samples of 2-month-old osteocyte-specific -catenin-de-
ficient and control littermate female mice. Neither M-CSF nor
RANKL expression was significantly altered in osteocyte-spe-
cific -catenin mutants compared to control mice (Fig. 7A and
B). However, consistent with OPG being a Wnt/-catenin tar-
get gene (19, 26, 69), OPG expression was significantly de-
creased by about 50% in femoral diaphyseal bone (Fig. 7C).
Conversely, serum RANKL protein concentration was ele-
vated by about 35% in osteocyte-specific -catenin-deficient
mice of either sex (Fig. 7D and data not shown).
To assess whether the observed gene expression differences
in femoral diaphyses from osteocyte-specific -catenin mutant
and control mice could indeed be due to changes in osteocytic
gene expression, as assumed given the abundance of osteocytes
in cortical bone relative to bone surface adherent osteoblasts,
TABLE 1. Bone structure and histomorphometric indices in the cancellous bone compartment of the distal femur metaphyses of control and
osteocyte-specific -catenin gene cKO mice
Bone structure parameter
or histomorphometric
indexa
Mean  SEM inb:
Female mice Male mice
Control cKOc Control cKOc
Tb.N (1/mm) 4.0  0.3 0.1  0.0** 5.3  0.3 0.2  0.6**
Tb.Th (m) 37.6  1.5 41.2  15.8 42.7  1.4 43.5  2.6
mBMD (mg/cm3) 820.7  9.1 793.9  28.0 795.5  8.9 793.8  16.3
dLS/BS (%) ND ND 41.1  4.3 36.2  9.5
MS/BS (%) ND ND 50.6  3.4 44.2  7.2
MAR (m/day) ND ND 1.6  0.1 2.0  0.1*
Ob.S/BS (%) ND ND 22.4  1.7 41.7  0.7**
OS/BS (%) ND ND 21.9  1.5 39.8  0.8**
a Abbreviations: BS, bone surface; dLS, double-labeled surface; MAR, mineral apposition rate; mBMD, material bone mineral density; MS, mineralizing surface;
Ob.S, osteoblast surface; OS, osteoid surface; Tb.N, trabecular number; Tb.Th, trabecular thickness.
b There were 2 to 11 mice in each group. ND, not determined.
c Values for the 2-month-old homozygous cKO mice that were significantly different from the value for control littermate mice of the same gender using unpaired
Student’s t tests are shown as follows: , P 
 0.05; , P 
 0.01.
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we next analyzed selective osteoblast- and osteocyte-enriched
cell populations obtained by sequential enzymatic digestion of
femoral diaphyses from 6-week-old osteocyte-specific -cate-
nin mutant and control male mice. Based on the respective
expression of osteocyte marker genes Dmp1 (10, 62) and Sost
(10, 57, 64, 68) as well as the osteoblast marker integrin binding
sialoprotein (6), fraction 6 was found to be strongly enriched in
osteocytes, while cell fraction 3 of control femora and fraction
one in homozygous osteocyte-specific -catenin mutants, re-
spectively, were identified as containing mostly osteoblasts
(Fig. 8B and data not shown). Cortical osteocytes of control
bone expressed about 40% higher levels of -catenin than
osteoblasts did, whereas this ratio was inverted in osteocyte-
specific -catenin mutant mice, indicating specific loss of
-catenin gene function in about 50% of cortical osteocytes
(Fig. 8A). Interestingly, at 6 weeks of age, femoral osteocytes
of control mice expressed considerably higher levels of the
osteoclastogenic regulators OPG and RANKL than femoral
osteoblasts (Fig. 8C and D). Moreover, osteocyte-specific
-catenin deficiency resulted in a selective decrease of OPG
expression in osteocytes relative to osteoblasts, whereas osteo-
cytic RANKL expression was not significantly altered (Fig. 8C
FIG. 5. Histomorphometric analysis of femoral bone of osteocyte-specific -catenin cKO mice. (A, C, E, and F) Quantification of the number
of osteoclasts (A and C) and bone formation rate (BFR) at endocortical (A and E) and cancellous (C and F) femoral bone surfaces in 2-month-old
homozygous (cKO), heterozygous (HET) osteocyte-specific -catenin-deficient and control mice. (B, C, D, and F) Representative images of TRAP
staining at the femoral endocortex of female mice (B [the arrows delineate the extent of cortices]) and the cancellous bone compartment in male
mice (D) or depicting fluorochrome marker labeling in male femora (C and F). (G and H) Quantification of serum osteocalcin levels (G) and ALP
levels (H) in 2-month-old mice. There were 2 to 11 mice in each group. Values for the mutant that were significantly different from the value for
control littermate mice using unpaired Student’s t tests are shown as follows: *, P 
 0.05; **, P 
 0.01. Bars, 50 m (B and D), 2 m (E), and
10 m (F).
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and D). Therefore, these data suggest that the selective de-
crease in osteocyte OPG expression contributes to the elevated
bone resorption present in osteocyte-specific -catenin-defi-
cient mice.
Finally, to determine whether cortical osteocytes also ex-
press significant levels of OPG and RANKL at skeletal matu-
rity, we performed quantitative gene expression analyses using
cellular fractions isolated from the femora of 4-month-old
wild-type mice. As in femora of younger mice, cell fractions 3
and 6 were identified as containing mostly osteoblasts or os-
teocytes, respectively, based on the relative expression levels of
the osteoblast marker gene ALP and the osteocyte marker
Dmp1 as well as other markers (Fig. 8E and F and data not
shown). Compared to skeletally growing mice, osteoblastic
OPG expression was increased, while osteoblastic RANKL ex-
pression was slightly lower. Importantly, cortical osteocytes of
skeletally mature mice expressed OPG and RANKL at levels
comparable to those found in osteoblasts (Fig. 8G and H).
DISCUSSION
Here, we describe the consequences of loss of Wnt/-catenin
signaling specifically in osteocytes using a conditional mouse
genetic approach (Ctnnb1loxP/loxP; Dmp1-Cre mice). Unexpect-
edly, osteocyte-specific deletion of the -catenin gene led to
early-onset, dramatic bone loss due to elevated osteoclast
number and activity, which correlated with the selective down-
TABLE 2. Histomorphometric indices in the distal femur metaphysis endocortex of control and osteocyte-specific -catenin cKO mice
Histomorphometric
indexa
Mean  SEM inb:
Female mice Male mice
Control cKOc Control cKOc
dLS/BS (%) 72.4  6.0 33.7  6.4** 78.1  4.0 49.7  5.2**
MS/BS (%) 77.0  5.2 43.3  4.5** 83.0  3.0 60.2  6.2*
MAR (m/day) 2.5  0.1 3.5  0.3* 3.1  0.2 4.6  1.1
Ob.S/BS (%) 80.0  2.1 67.2  5.5 42.7  2.4 52.9  11.5
OS/BS (%) 73.9  2.3 61.7  5.4 46.1  3.2 53.8  10.8
Oc.S/BS (%) 2.4  0.4 17.1  1.5** 2.6  0.6 13.2  1.7*
ES/BS (%) 1.1  0.4 42.6  5.6** 3.3  0.6 26.0  8.0**
a Abbreviations: BS, bone surface; dLS, double-labeled surface; ES, eroded surface; MAR, mineral apposition rate; MS, mineralizing surface; Ob.S, osteoblast
surface; Oc.S, osteoclast surface; OS, osteoid surface.
b There were 3 to 11 mice in each group.
c Values for 2-month-old homozygous cKO mice that were significantly different from the value for control littermate mice of the same gender using unpaired
Student’s t tests are shown as follows: , P 
 0.05; , P 
 0.01.
FIG. 6. Analysis of femoral cortical osteocyte number and apopto-
sis in osteocyte-specific -catenin cKO mice. (A to C) Quantification of
relative expression of the proapoptotic marker genes BCL2-like 11/Bim
(A) and Bax (B) normalized to 18S and osteocyte density (C) in
femoral cortical bone of homozygous (cKO) and heterozygous (HET)
-catenin-deficient and control female mice. N.Ot/mm2, number of
osteocytes per square millimeter. (D) Representative confocal micro-
scopic images depicting TUNEL-positive osteocytes (green) express-
ing the osteocyte marker sclerostin (red) in femoral cortex of P14
homozygous cKO and control mice. There were 3 to 11 mice in each
group.
FIG. 7. Analysis of the levels of expression of osteoclastic differ-
entiation factors in osteocyte-specific -catenin cKO mice. (A to C)
The level of expression normalized to 18S of M-CSF (A), RANKL (B),
and OPG (C) in cortical bone of femur diaphyses from 2-month-old
homozygous (cKO) and heterozygous (HET) -catenin-deficient and
control littermate female mice. (D) Quantification of RANKL protein
in serum of 2-month-old homozygous (cKO) and heterozygous (HET)
-catenin-deficient and control littermate males. There were 4 to 9
mice in each group. Values for the mutant that were significantly
different (P 
 0.05) from the value for control littermate mice using
unpaired Student’s t tests are indicated (*).
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regulation of the anti-osteoclastogenic factor OPG in cortical
osteocytes. Analysis of -catenin expression in femoral diges-
tion fractions confirmed that -catenin expression was indeed
specifically downregulated in osteocytes but was normal in
femoral osteoblast-enriched cell fractions of Ctnnb1loxP/loxP;
Dmp1-Cre mice. While specific, -catenin expression in femo-
ral osteocyte fractions was however reduced by only about 50%
compared to control osteocytes. Thus, Dmp1-Cre-mediated ho-
mozygous deletion of -catenin gene function in osteocytes was
incomplete, in line with previous observations (42). Despite
this caveat of the transgenic Dmp1-Cre driver line, the bone
phenotypic consequences of the partial loss of osteocyte
-catenin activity were dramatic, thus underscoring the impor-
tance of Wnt/-catenin signaling in osteocytes for normal bone
homeostasis.
Overall, the phenotype of osteocyte-specific -catenin cKO
mice strongly resembles the one described for osteoblast-tar-
geted -catenin-deficient mice (19, 26). Since in osteoblast-
targeted cKO mice, -catenin was deleted from the osteoblast
stage of the mesenchymal cell lineage onwards, it was not only
removed in osteoblasts but also in their cellular descendants,
including osteocytes. Thus, it is likely that loss of -catenin
gene function in osteocytes contributed to the observed bone
resorption phenotype present in osteoblast-targeted -catenin-
deficient mice. Yet, -catenin deficiency induced at the early
osteoblast stage by Col11-Cre caused only a comparably mild
bone loss, and homozygous mutants displayed a normal life
span (19). This might be explained by differences in genetic
background as well as incomplete genetic penetrance of
Col11-Cre-mediated -catenin gene recombination (19). In
contrast, the phenotype of OC-Cre-driven -catenin deficiency
leading to the loss of -catenin from the late osteoblast stage
onwards was slightly more severe in terms of lethality com-
pared to osteocyte-specific -catenin mutants (26). Whereas
OC-Cre-dependent -catenin mutant mice died within 30 to 45
days after birth, Dmp1-Cre-induced mutants were viable for a
few months. Although the low-bone-mass phenotypes of both
models appear qualitatively similar, the absolute decrease in
relative cancellous bone volume and BMD cannot be directly
compared due to differences in the respective applied meth-
odology (26).
In line with overlapping as well as distinct functions of Wnt/
-catenin signaling in osteoblasts and osteocytes, deletion of
-catenin in late osteoblasts using OC-Cre resulted in de-
creased osteoblast numbers in vivo (26). In contrast, osteoblast
numbers and osteocyte density were normal in osteocyte-specific
-catenin-deficient mice. Moreover, it has been demonstrated
that osteoblasts lacking -catenin enhance osteoclastogenesis in
vitro (19). As expected and consistent with the osteocyte speci-
ficity of our model, in vitro coculture experiments did not
reveal induction of increased osteoclastogenesis by osteoblasts
derived from osteocyte-specific -catenin cKO mice (data not
shown). Furthermore, whereas in cultured -catenin-deficient
osteoblasts, expression of the late osteoblastic differentiation
marker osteocalcin was reduced and mineralized nodule for-
mation was diminished (26), serum osteocalcin levels were
normal in osteocyte-specific -catenin cKO mice. We formally
cannot exclude a minor delay in bone matrix mineralization in
osteocyte-specific -catenin mutants, since osteoid surface was
significantly increased in the cancellous bone compartment.
However, this was not observed at the endocortex. Moreover,
as osteoblast surface and osteoblastic mineral apposition rates
were also elevated, the increase in trabecular osteoid surface
probably reflects enhanced osteoblastic matrix deposition in an
attempt to compensate for the vast bone loss occurring in
osteocyte-specific -catenin-deficient mice. In line with largely
FIG. 8. Analysis of the levels of expression of osteoclastic differ-
entiation factors in osteoblast- and osteocyte-enriched femoral bone
fractions. (A to D) Relative expression of -catenin (A), the osteocyte
marker Dmp1 (B), and osteoclastic differentiation regulators OPG
(C) and RANKL (D) in osteoblast (Ob)- and osteocyte (Ot)-enriched
femoral bone fractions from 6-week-old homozygous (cKO) -catenin-
deficient and control littermate male mice. (E to H) Expression nor-
malized to 18S for the osteoblast marker ALP (E), the osteocyte
marker Dmp1 (F), and osteoclast regulators OPG (G) and RANKL
(H) in osteoblast (Ob)- and osteocyte (Ot)-enriched fractions of fem-
ora from 4-month-old skeletally mature wild-type female mice. The
threshold cycle (Ct) values for each marker are indicated for osteoblast
(A to H)- and osteocyte (E to H)- enriched fractions. There were 2 to
5 mice in each group. Values for the osteblast fraction that were
significantly different from the value for the osteocyte fraction using
paired Student’s t tests are shown as follows: *, P 
 0.05; **, P 
 0.01.
Values for the mutant mice that were significantly different from the
value for control littermate mice using unpaired Student’s t tests are
shown as follows: x, P 
 0.05; xx, P 
 0.01.
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undisturbed bone formation, trabecular thickness and material
BMD were not significantly altered in osteocyte-specific
-catenin mutants, indicating that in general, mineralization
was normal in osteocyte-specific -catenin cKO mice. In addi-
tion, the histomorphometric analysis of the cancellous bone
compartment was somewhat hampered by the fact that very
little trabecular bone surface was available in osteocyte-specific
-catenin mutants. This may also explain the seemingly sur-
prising finding that the number of osteoclasts was only mildly
increased on trabecular bone compared to endosteal bone
surfaces. Hence, it appears that the enhanced phenotypic se-
verity of OC-Cre-driven osteoblast versus Dmp1-Cre-depen-
dent osteocyte -catenin deficiency could be due to the selec-
tive decrease in osteoblast number and activity in OC-Cre- but
not in Dmp1-Cre-dependent -catenin mutant mice. In con-
trast, both mouse models revealed a comparable elevation in
osteoclastic bone resorption parameters, indicating that
-catenin expression in osteocytes is at least equally important
for control of bone resorption as it is in osteoblasts.
Osteoclasts have recently been shown to stimulate osteoblast
differentiation by secreting Wnt ligands and chemoattractants,
thereby contributing to coupling of bone resorption and for-
mation during skeletal remodeling (54). Conversely, cells of
the osteoblast lineage are known to impact osteoclastogenesis
in a non-cell-autonomous fashion by expressing the osteoclast
differentiation factor RANKL and its decoy receptor OPG (24,
46). In line with previous findings by us and others (34, 51, 71,
73), cellular fractionation by sequential digestion of femoral
diaphyses revealed that primary osteocytes in skeletally grow-
ing mice and mature mice robustly express OPG and RANKL
at levels exceeding or comparable to those present in osteo-
blasts. Although it is currently unclear whether osteocyte-ex-
pressed cytokines are indeed released into the lacunar-cana-
licular network, theoretical models and tracer experiments
have demonstrated that small globular proteins of up to 7 nm
in diameter and 70 kDa, the estimated size of serum albumin,
can pass through the osteocyte canalicular system (60, 66, 67).
Therefore, theoretically, molecules of the size of monomeric
OPG (60 kDa), but not soluble RANKL, which is thought to be
a nondisulfide-linked homotrimer (35), may pass through the
osteocyte lacunar-canalicular system. In addition, osteocytes
might secrete other small modulators of osteoclast and/or os-
teoblast function and diffusible chemoattractants or chemore-
pellents to establish local chemotactic gradients that might
specifically guide osteoclasts and/or osteoblasts or their respec-
tive precursors to sites of local bone turnover at the bone
surface and/or intracortical bone-vascular endothelial inter-
faces (14, 20, 23, 34, 45).
The level of expression of OPG increased in osteoblast-
targeted -catenin gain-of-function mice (19). Conversely, it
was found to be decreased in osteoblast- as well as osteocyte-
specific -catenin cKO mouse models, providing a putative
molecular mechanism contributing to the observed increase in
osteoclastic bone resorption (19, 26). However, given the
slightly less severe low-bone-mass phenotype of constitutive
OPG loss-of-function mice, which is characterized by a high
bone turnover state of excessive bone resorption and elevated
bone formation (15, 48), downregulation of OPG alone cannot
fully account for the observed phenotype of osteoblast- and
osteocyte-targeted -catenin-deficient mice.
In osteoblast-targeted -catenin-deficient mice, RANKL ex-
pression was not significantly altered in vivo (19). Yet, it was
increased in cultured primary calvarial osteoblasts lacking
-catenin function, whereas the converse was found in osteo-
blasts from Wnt/-catenin gain-of-function mice (26). Interest-
ingly, in osteocyte-specific -catenin mutant mice, serum
RANKL levels were slightly increased, whereas RANKL ex-
pression in cortical bone remained normal. There are several
conceivable putative mechanisms that may underlie the ob-
served increase in serum RANKL in osteocyte-specific -cate-
nin cKO mice. It is possible that loss of -catenin function in
osteocytes may induce a signal transferred from osteocytes to
osteoblasts and/or bone marrow stroma cells that causes up-
regulation of RANKL expression in these cell types in a non-
cell-autonomous manner. Conversely, it is conceivable that
Wnt/-catenin signaling in osteocytes might control expression
of a negative regulator of RANKL expression. Alternatively, as
only soluble RANKL, not surface-bound RANKL, is detected,
increased release of cell surface-bound RANKL may have
occurred in osteocyte-specific -catenin-deficient mice. Finally,
the increase in serum RANKL may be directly linked to the
decreased osteocyte expression of OPG, as RANKL bound
to OPG was not detected by our assay. If true, the level of
osteocyte-expressed RANKL should determine the relative
fraction of osteocyte-secreted OPG that is complexed and
thus trapped in the osteocyte lacunar-canalicular system as
opposed to unbound OPG that may pass through the cana-
licular system into circulation to exert its antiosteoclastic
function. In line with this interpretation, the amount of
detectable RANKL would thus increase in circulation with
reduced osteocytic secretion of OPG. Furthermore, we no-
ticed that osteocyte OPG expression levels were consider-
ably smaller, while osteocyte RANKL expression levels were
slightly higher in skeletally growing control mice undergoing
bone modeling and high bone turnover compared to skele-
tally mature wild-type mice. This thus further suggests that
the osteocyte RANKL/OPG expression ratio is critical for
control of bone homeostasis. While at present, we can nei-
ther distinguish between these possibilities nor do we know
the cellular source of the measured serum RANKL, the net
outcome will be the same, namely, an increase in RANKL/
OPG ratio favoring osteoclastogenesis and osteoclast sur-
vival in osteocyte-specific -catenin mutant mice. Interest-
ingly, in MLO-Y4 osteocyte-like cells, which express
RANKL and OPG (73), the RANKL/OPG ratio decreases
when cells are subjected to shear stress (71). This suggests
that mechanical load reduces the soluble RANKL/OPG ra-
tio, preventing osteoclast activation by osteocytes. Hence,
one may speculate that mechanosensation and/or transduc-
tion might be compromised in -catenin-deficient osteo-
cytes, in line with previous findings implicating Wnt/-cate-
nin signaling in osteocyte mechanotransduction (11, 39,
56–58).
Wnt/-catenin signaling has been implicated in the regula-
tion of apoptotic cell death of cells of the osteoblast lineage in
some instances (4, 7, 39), but not others (5, 31, 69). Moreover,
osteocyte apoptosis correlates with increased osteoclast re-
cruitment and bone resorption (1, 16, 20, 22, 34, 49, 61). While
the underlying reason for the decreased osteoblast number in
osteoblast-specific OC-Cre-directed -catenin cKO mice was
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not reported (26), TUNEL analyses of Col11-Cre-mediated
osteoblast-specific -catenin gain- or loss-of-function mutant
mice revealed normal levels of programmed cell death (19).
Consistent with these reports, cortical osteocyte density and
apoptotic marker gene expression were normal in 2-month-old
osteocyte-specific -catenin-deficient mice and TUNEL stain-
ing in 2-week-old -catenin cKO mice was comparable to con-
trol littermate mice. This suggests that -catenin is not re-
quired for osteocyte viability but that it plays a role is osteocyte
signaling.
With respect to gender specificity, we found that progression
of bone loss was faster and for most parameters analyzed, such
as bone mass, cortical width, serum creatine kinase level, and
osteoclast eroded surface, slightly more severe in female than
male osteocyte-specific -catenin-deficient mice. Gender-spe-
cific enhanced sensitivity of female mice toward modulation of
Wnt/-catenin signaling was also reported for other loss-of-
function mutants of Wnt/-catenin signaling components (37,
50, 72). Whether these observations are due to cross talk of
Wnt/-catenin and sex steroid signaling pathways or related to
sexually dimorphic bone mass accrual, bone turnover, and/or
osteocyte mechanotransduction (3, 41, 59, 72) is currently un-
known and remains to be addressed by future studies.
Finally, in addition to being an essential mediator of canon-
ical Wnt signaling, -catenin also binds to cadherins and
-catenin at adherens junctions linking cell adhesion to the
actin cytoskeleton (47). Moreover, under conditions of ele-
vated oxidative stress, -catenin has been found to associate
with forkhead box O (FoxO) transcription factors to upregu-
late expression of oxidative stress response target genes at the
expense of canonical Wnt target gene transcription (2, 44).
Therefore, we currently do not exclude the possibility that in
addition to blocking Wnt/-catenin signaling as demonstrated
by decreased expression of canonical Wnt target genes, other
signaling pathways might be compromised in osteocyte-specific
-catenin loss-of-function mice. Future investigations will need
to assess the roles of these signaling pathways and of non-
canonical Wnt signaling in osteocytes in vivo.
Together our findings reveal a previously underestimated
novel important function for Wnt/-catenin signaling in osteo-
cytes. In particular, we demonstrate that osteocyte -catenin is
required for expression of the antiosteoclastogenic factor OPG
in osteocytes and that osteocytes express RANKL and OPG at
levels comparable to or exceeded those of osteoblasts. These
data suggest that the RANKL/OPG ratio expressed by osteo-
cytes may determine osteoclast recruitment and activation,
which is in line with the long-standing hypothesis of osteocytes
being key regulators of bone homeostasis.
ACKNOWLEDGMENTS
This study was partially supported by the Novartis Institutes for
BioMedical Research Education Office Postdoctoral Fellowship
Program (I.K.) and by NIH NIAMS PO1 AR046798 (L.F.B. and
J.Q.F.).
We thank Tanja Grabensta¨tter, Gabriela Guiglia, Peter Ingold,
Heidi Jeker, Marcel Merdes, Philippe Scheubel, Renzo Schumpf, An-
drea Venturiere, Carrie Zhao, and Mark Dallas for excellent technical
assistance as well as Keiko Petrosky for providing vertebral CT data
and David Ledieu for clinical blood biochemistry data.
REFERENCES
1. Aguirre, J. I., L. I. Plotkin, S. A. Stewart, R. S. Weinstein, A. M. Parfitt, S. C.
Manolagas, and T. Bellido. 2006. Osteocyte apoptosis is induced by weight-
lessness in mice and precedes osteoclast recruitment and bone loss. J. Bone
Miner. Res. 21:605–615.
2. Almeida, M., L. Han, M. Martin-Millan, C. A. O’Brien, and S. C. Manol-
agas. 2007. Oxidative stress antagonizes Wnt signaling in osteoblast precur-
sors by diverting beta-catenin from T cell factor- to forkhead box O-medi-
ated transcription. J. Biol. Chem. 282:27298–27305.
3. Armstrong, V. J., M. Muzylak, A. Sunters, G. Zaman, L. K. Saxon, J. S.
Price, and L. E. Lanyon. 2007. Wnt/beta-catenin signaling is a component of
osteoblastic bone cell early responses to load-bearing and requires estrogen
receptor alpha. J. Biol. Chem. 282:20715–20727.
4. Babij, P., W. Zhao, C. Small, Y. Kharode, P. J. Yaworsky, M. L. Bouxsein,
P. S. Reddy, P. V. Bodine, J. A. Robinson, B. Bhat, J. Marzolf, R. A. Moran,
and F. Bex. 2003. High bone mass in mice expressing a mutant LRP5 gene.
J. Bone Miner. Res. 18:960–974.
5. Bennett, C. N., H. Ouyang, Y. L. Ma, Q. Zeng, I. Gerin, K. M. Sousa, T. F.
Lane, V. Krishnan, K. D. Hankenson, and O. A. MacDougald. 2007. Wnt10b
increases postnatal bone formation by enhancing osteoblast differentiation.
J. Bone Miner. Res. 22:1924–1932.
6. Benson, M. D., J. E. Aubin, G. Xiao, P. E. Thomas, and R. T. Franceschi.
1999. Cloning of a 2.5 kb murine bone sialoprotein promoter fragment and
functional analysis of putative Osf2 binding sites. J. Bone Miner. Res. 14:
396–405.
7. Bodine, P. V., W. Zhao, Y. P. Kharode, F. J. Bex, A. J. Lambert, M. B. Goad,
T. Gaur, G. S. Stein, J. B. Lian, and B. S. Komm. 2004. The Wnt antagonist
secreted frizzled-related protein-1 is a negative regulator of trabecular bone
formation in adult mice. Mol. Endocrinol. 18:1222–1237.
8. Bonewald, L. F. 2005. Generation and function of osteocyte dendritic pro-
cesses. J. Musculoskelet. Neuronal Interact. 5:321–324.
9. Bonewald, L. F. 2006. Mechanosensation and transduction in osteocytes.
Bonekey Osteovision 3:7–15.
10. Bonewald, L. F. 2007. Osteocytes as dynamic multifunctional cells. Ann.
N. Y. Acad. Sci. 1116:281–290.
11. Bonewald, L. F., and M. L. Johnson. 2008. Osteocytes, mechanosensing and
Wnt signaling. Bone 42:606–615.
12. Boyce, B. F., and L. Xing. 2008. Functions of RANKL/RANK/OPG in bone
modeling and remodeling. Arch. Biochem. Biophys. 473:139–146.
13. Brault, V., R. Moore, S. Kutsch, M. Ishibashi, D. H. Rowitch, A. P. McMa-
hon, L. Sommer, O. Boussadia, and R. Kemler. 2001. Inactivation of the
beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain
malformation and failure of craniofacial development. Development 128:
1253–1264.
14. Breuil, V., H. Schmid-Antomarchi, A. Schmid-Alliana, R. Rezzonico, L.
Euller-Ziegler, and B. Rossi. 2003. The receptor activator of nuclear factor
(NF)-kappaB ligand (RANKL) is a new chemotactic factor for human
monocytes. FASEB J. 17:1751–1753.
15. Bucay, N., I. Sarosi, C. R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S.
Scully, H. L. Tan, W. Xu, D. L. Lacey, W. J. Boyle, and W. S. Simonet. 1998.
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial
calcification. Genes Dev. 12:1260–1268.
16. Cardoso, L., B. C. Herman, O. Verborgt, D. Laudier, R. J. Majeska, and
M. B. Schaffler. 2009. Osteocyte apoptosis controls activation of intracortical
resorption in response to bone fatigue. J. Bone Miner. Res. 24:597–605.
17. Caverzasio, J. 2009. Non-canonical Wnt signaling: what is its role in bone?
Bonekey 6:107–115.
18. Day, T. F., X. Guo, L. Garrett-Beal, and Y. Yang. 2005. Wnt/beta-catenin
signaling in mesenchymal progenitors controls osteoblast and chondrocyte
differentiation during vertebrate skeletogenesis. Dev. Cell 8:739–750.
19. Glass, D. A., II, P. Bialek, J. D. Ahn, M. Starbuck, M. S. Patel, H. Clevers,
M. M. Taketo, F. Long, A. P. McMahon, R. A. Lang, and G. Karsenty. 2005.
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast
differentiation. Dev. Cell 8:751–764.
20. Gu, G., M. Mulari, Z. Peng, T. A. Hentunen, and H. K. Vaananen. 2005.
Death of osteocytes turns off the inhibition of osteoclasts and triggers local
bone resorption. Biochem. Biophys. Res. Commun. 335:1095–1101.
21. Gu, G., M. Nars, T. A. Hentunen, K. Metsikko, and H. K. Vaananen. 2006.
Isolated primary osteocytes express functional gap junctions in vitro. Cell
Tissue Res. 323:263–271.
22. Hedgecock, N. L., T. Hadi, A. A. Chen, S. B. Curtiss, R. B. Martin, and S. J.
Hazelwood. 2007. Quantitative regional associations between remodeling,
modeling, and osteocyte apoptosis and density in rabbit tibial midshafts.
Bone 40:627–637.
23. Heino, T. J., T. A. Hentunen, and H. K. Vaananen. 2004. Conditioned
medium from osteocytes stimulates the proliferation of bone marrow mes-
enchymal stem cells and their differentiation into osteoblasts. Exp. Cell Res.
294:458–468.
24. Henriksen, K., A. V. Neutzsky-Wulff, L. F. Bonewald, and M. A. Karsdal.
2009. Local communication on and within bone controls bone remodeling.
Bone 44:1026–1033.
VOL. 30, 2010 -CATENIN SIGNALING IN OSTEOCYTES 3083
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
25. Hill, T. P., D. Spater, M. M. Taketo, W. Birchmeier, and C. Hartmann. 2005.
Canonical Wnt/beta-catenin signaling prevents osteoblasts from differenti-
ating into chondrocytes. Dev. Cell 8:727–738.
26. Holmen, S. L., C. R. Zylstra, A. Mukherjee, R. E. Sigler, M. C. Faugere,
M. L. Bouxsein, L. Deng, T. L. Clemens, and B. O. Williams. 2005. Essential
role of beta-catenin in postnatal bone acquisition. J. Biol. Chem. 280:21162–
21168.
27. Hu, H., M. J. Hilton, X. Tu, K. Yu, D. M. Ornitz, and F. Long. 2005.
Sequential roles of Hedgehog and Wnt signaling in osteoblast development.
Development 132:49–60.
28. Inouye, M. 1976. Differential staining of cartilage and bone in fetal mouse
skeleton by alcian blue and alizarin red-S. Congen. Anom. 16:171–173.
29. Jho, E. H., T. Zhang, C. Domon, C. K. Joo, J. N. Freund, and F. Costan-
tini. 2002. Wnt/beta-catenin/Tcf signaling induces the transcription of
Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol.
22:1172–1183.
30. Kamioka, H., T. Honjo, and T. Takano-Yamamoto. 2001. A three-dimen-
sional distribution of osteocyte processes revealed by the combination of
confocal laser scanning microscopy and differential interference contrast
microscopy. Bone 28:145–149.
31. Kato, M., M. S. Patel, R. Levasseur, I. Lobov, B. H. Chang, D. A. Glass II,
C. Hartmann, L. Li, T. H. Hwang, C. F. Brayton, R. A. Lang, G. Karsenty,
and L. Chan. 2002. Cbfa1-independent decrease in osteoblast proliferation,
osteopenia, and persistent embryonic eye vascularization in mice deficient in
Lrp5, a Wnt coreceptor. J. Cell Biol. 157:303–314.
32. Keller, H., and M. Kneissel. 2005. SOST is a target gene for PTH in bone.
Bone 37:148–158.
33. Kneissel, M., A. Boyde, and J. A. Gasser. 2001. Bone tissue and its miner-
alization in aged estrogen-depleted rats after long-term intermittent treat-
ment with parathyroid hormone (PTH) analog SDZ PTS 893 or human
PTH(1-34). Bone 28:237–250.
34. Kurata, K., T. J. Heino, H. Higaki, and H. K. Vaananen. 2006. Bone marrow
cell differentiation induced by mechanically damaged osteocytes in 3D gel-
embedded culture. J. Bone Miner. Res. 21:616–625.
35. Lam, J., C. A. Nelson, F. P. Ross, S. L. Teitelbaum, and D. H. Fremont. 2001.
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of
receptor-ligand specificity. J. Clin. Invest. 108:971–979.
36. Leung, J. Y., F. T. Kolligs, R. Wu, Y. Zhai, R. Kuick, S. Hanash, K. R. Cho,
and E. R. Fearon. 2002. Activation of AXIN2 expression by beta-catenin-T
cell factor. A feedback repressor pathway regulating Wnt signaling. J. Biol.
Chem. 277:21657–21665.
37. Li, X., M. S. Ominsky, Q. T. Niu, N. Sun, B. Daugherty, D. D’Agostin, C.
Kurahara, Y. Gao, J. Cao, J. Gong, F. Asuncion, M. Barrero, K. Warming-
ton, D. Dwyer, M. Stolina, S. Morony, I. Sarosi, P. J. Kostenuik, D. L. Lacey,
W. S. Simonet, H. Z. Ke, and C. Paszty. 2008. Targeted deletion of the
sclerostin gene in mice results in increased bone formation and bone
strength. J. Bone Miner. Res. 23:860–869.
38. Liang, M., G. Russell, and P. A. Hulley. 2008. Bim, Bak, and Bax regulate
osteoblast survival. J. Bone Miner. Res. 23:610–620.
39. Lin, C., X. Jiang, Z. Dai, X. Guo, T. Weng, J. Wang, Y. Li, G. Feng, X. Gao,
and L. He. 2009. Sclerostin mediates bone response to mechanical unloading
through antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res. 24:
1651–1661.
40. Liu, F., S. Kohlmeier, and C. Y. Wang. 2008. Wnt signaling and skeletal
development. Cell Signal. 20:999–1009.
41. Liu, X. H., A. Kirschenbaum, S. Yao, and A. C. Levine. 2007. Androgens
promote preosteoblast differentiation via activation of the canonical Wnt
signaling pathway. Ann. N. Y. Acad. Sci. 1116:423–431.
42. Lu, Y., Y. Xie, S. Zhang, V. Dusevich, L. F. Bonewald, and J. Q. Feng. 2007.
DMP1-targeted Cre expression in odontoblasts and osteocytes. J. Dent. Res.
86:320–325.
43. Lustig, B., B. Jerchow, M. Sachs, S. Weiler, T. Pietsch, U. Karsten, M. van
de Wetering, H. Clevers, P. M. Schlag, W. Birchmeier, and J. Behrens. 2002.
Negative feedback loop of Wnt signaling through upregulation of conductin/
axin2 in colorectal and liver tumors. Mol. Cell. Biol. 22:1184–1193.
44. Manolagas, S. C., and M. Almeida. 2007. Gone with the Wnts: beta-
catenin, T-cell factor, forkhead box O, and oxidative stress in age-depen-
dent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol.
21:2605–2614.
45. Martin, R. B. 2000. Does osteocyte formation cause the nonlinear refilling of
osteons? Bone 26:71–78.
46. Martin, T., J. H. Gooi, and N. A. Sims. 2009. Molecular mechanisms in
coupling of bone formation to resorption. Crit. Rev. Eukaryot. Gene Expr.
19:73–88.
47. Mbalaviele, G., C. S. Shin, and R. Civitelli. 2006. Cell-cell adhesion and
signaling through cadherins: connecting bone cells in their microenviron-
ment. J. Bone Miner. Res. 21:1821–1827.
48. Mizuno, A., N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato,
N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima,
N. Washida, E. Tsuda, T. Morinaga, K. Higashio, and H. Ozawa. 1998.
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/
osteoprotegerin. Biochem. Biophys. Res. Commun. 247:610–615.
49. Noble, B. S., N. Peet, H. Y. Stevens, A. Brabbs, J. R. Mosley, G. C. Reilly, J.
Reeve, T. M. Skerry, and L. E. Lanyon. 2003. Mechanical loading: biphasic
osteocyte survival and targeting of osteoclasts for bone destruction in rat
cortical bone. Am. J. Physiol. Cell Physiol. 284:C934–C943.
50. Noh, T., Y. Gabet, J. Cogan, Y. Shi, A. Tank, T. Sasaki, B. Criswell, A. Dixon,
C. Lee, J. Tam, T. Kohler, E. Segev, L. Kockeritz, J. Woodgett, R. Muller, Y.
Chai, E. Smith, I. Bab, and B. Frenkel. 2009. Lef1 haploinsufficient mice
display a low turnover and low bone mass phenotype in a gender- and
age-specific manner. PLoS One 4:e5438.
51. Onyia, J. E., R. R. Miles, X. Yang, D. L. Halladay, J. Hale, A. Glasebrook, D.
McClure, G. Seno, L. Churgay, S. Chandrasekhar, and T. J. Martin. 2000.
In vivo demonstration that human parathyroid hormone 1-38 inhibits the
expression of osteoprotegerin in bone with the kinetics of an immediate early
gene. J. Bone Miner. Res. 15:863–871.
52. Paic, F., J. C. Igwe, R. Nori, M. S. Kronenberg, T. Franceschetti, P. Har-
rington, L. Kuo, D. G. Shin, D. W. Rowe, S. E. Harris, and I. Kalajzic. 2009.
Identification of differentially expressed genes between osteoblasts and os-
teocytes. Bone 45:682–692.
53. Parfitt, A. M., M. K. Drezner, F. H. Glorieux, J. A. Kanis, H. Malluche,
P. J. Meunier, S. M. Ott, and R. R. Recker. 1987. Bone histomorphom-
etry: standardization of nomenclature, symbols, and units. Report of the
ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner.
Res. 2:595–610.
54. Pederson, L., M. Ruan, J. J. Westendorf, S. Khosla, and M. J. Oursler. 2008.
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling
and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. U. S. A.
105:20764–20769.
55. Piters, E., E. Boudin, and W. Van Hul. 2008. Wnt signaling: a win for bone.
Arch. Biochem. Biophys. 473:112–116.
56. Robinson, J. A., M. Chatterjee-Kishore, P. J. Yaworsky, D. M. Cullen, W.
Zhao, C. Li, Y. Kharode, L. Sauter, P. Babij, E. L. Brown, A. A. Hill, M. P.
Akhter, M. L. Johnson, R. R. Recker, B. S. Komm, and F. J. Bex. 2006.
Wnt/beta-catenin signaling is a normal physiological response to mechanical
loading in bone. J. Biol. Chem. 281:31720–31728.
57. Robling, A. G., P. J. Niziolek, L. A. Baldridge, K. W. Condon, M. R. Allen,
I. Alam, S. M. Mantila, J. Gluhak-Heinrich, T. M. Bellido, S. E. Harris, and
C. H. Turner. 2008. Mechanical stimulation of bone in vivo reduces osteocyte
expression of Sost/sclerostin. J. Biol. Chem. 283:5866–5875.
58. Sawakami, K., A. G. Robling, M. Ai, N. D. Pitner, D. Liu, S. J. Warden, J. Li,
P. Maye, D. W. Rowe, R. L. Duncan, M. L. Warman, and C. H. Turner. 2006.
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but
not for the anabolic bone response to parathyroid hormone treatment.
J. Biol. Chem. 281:23698–23711.
59. Shah, S., A. Hecht, R. Pestell, and S. W. Byers. 2003. Trans-repression of
beta-catenin activity by nuclear receptors. J. Biol. Chem. 278:48137–48145.
60. Tami, A. E., M. B. Schaffler, and M. L. Knothe Tate. 2003. Probing the tissue
to subcellular level structure underlying bone’s molecular sieving function.
Biorheology 40:577–590.
61. Tatsumi, S., K. Ishii, N. Amizuka, M. Li, T. Kobayashi, K. Kohno, M. Ito, S.
Takeshita, and K. Ikeda. 2007. Targeted ablation of osteocytes induces
osteoporosis with defective mechanotransduction. Cell Metab. 5:464–475.
62. Toyosawa, S., S. Shintani, T. Fujiwara, T. Ooshima, A. Sato, N. Ijuhin, and
T. Komori. 2001. Dentin matrix protein 1 is predominantly expressed in
chicken and rat osteocytes but not in osteoblasts. J. Bone Miner. Res.
16:2017–2026.
63. Vaananen, H. K., and T. Laitala-Leinonen. 2008. Osteoclast lineage and
function. Arch. Biochem. Biophys. 473:132–138.
64. van Bezooijen, R. L., B. A. Roelen, A. Visser, L. van der Wee-Pals, E. de
Wilt, M. Karperien, H. Hamersma, S. E. Papapoulos, P. ten Dijke, and
C. W. Lowik. 2004. Sclerostin is an osteocyte-expressed negative regulator
of bone formation, but not a classical BMP antagonist. J. Exp. Med.
199:805–814.
65. Verborgt, O., N. A. Tatton, R. J. Majeska, and M. B. Schaffler. 2002.
Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue:
complementary roles in bone remodeling regulation? J. Bone Miner. Res.
17:907–914.
66. Wang, L., C. Ciani, S. B. Doty, and S. P. Fritton. 2004. Delineating bone’s
interstitial fluid pathway in vivo. Bone 34:499–509.
67. Weinbaum, S., S. C. Cowin, and Y. Zeng. 1994. A model for the excitation of
osteocytes by mechanical loading-induced bone fluid shear stresses. J. Bio-
mech. 27:339–360.
68. Winkler, D. G., M. K. Sutherland, J. C. Geoghegan, C. Yu, T. Hayes, J. E.
Skonier, D. Shpektor, M. Jonas, B. R. Kovacevich, K. Staehling-Hamp-
ton, M. Appleby, M. E. Brunkow, and J. A. Latham. 2003. Osteocyte
control of bone formation via sclerostin, a novel BMP antagonist. EMBO
J. 22:6267–6276.
69. Yan, Y., D. Tang, M. Chen, J. Huang, R. Xie, J. H. Jonason, X. Tan, W.
Hou, D. Reynolds, W. Hsu, S. E. Harris, J. E. Puzas, H. Awad, R. J.
O’Keefe, B. F. Boyce, and D. Chen. 2009. Axin2 controls bone remodeling
through the -catenin–BMP signaling pathway in adult mice. J. Cell Sci.
122:3566–3578.
70. Yochum, G. S., S. McWeeney, V. Rajaraman, R. Cleland, S. Peters, and R. H.
3084 KRAMER ET AL. MOL. CELL. BIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
Goodman. 2007. Serial analysis of chromatin occupancy identifies beta-cate-
nin target genes in colorectal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A.
104:3324–3329.
71. You, L., S. Temiyasathit, P. Lee, C. H. Kim, P. Tummala, W. Yao, W.
Kingery, A. M. Malone, R. Y. Kwon, and C. R. Jacobs. 2008. Osteocytes as
mechanosensors in the inhibition of bone resorption due to mechanical
loading. Bone 42:172–179.
72. Zaman, G., H. L. Jessop, M. Muzylak, R. L. De Souza, A. A. Pitsillides, J. S.
Price, and L. L. Lanyon. 2006. Osteocytes use estrogen receptor alpha to
respond to strain but their ERalpha content is regulated by estrogen. J. Bone
Miner. Res. 21:1297–1306.
73. Zhao, S., Y. K. Zhang, S. Harris, S. S. Ahuja, and L. F. Bonewald. 2002.
MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
J. Bone Miner. Res. 17:2068–2079.
VOL. 30, 2010 -CATENIN SIGNALING IN OSTEOCYTES 3085
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
